Fischer Medical Ventures soars on collaborating with Nanyang Biologics
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Fischer Medical Ventures is currently trading at Rs. 605.95, up by 8.90 points or 1.49% from its previous closing of Rs. 597.05 on the BSE.
The scrip opened at Rs. 607.95 and has touched a high and low of Rs. 608.80 and Rs. 597.05 respectively. So far 484 shares were traded on the counter.
The BSE group 'T' stock of face value Rs. 10 has touched a 52 week high of Rs. 792.65 on 14-Jun-2024 and a 52 week low of Rs. 66.80 on 04-Oct-2023.
Last one week high and low of the scrip stood at Rs. 622.85 and Rs. 580.00 respectively. The current market cap of the company is Rs. 3231.40 crore.
The promoters holding in the company stood at 74.91%, while Institutions and Non-Institutions held 6.75% and 18.33% respectively.
Fischer Medical Ventures (Fischer MV) has collaborated with Singapore company, Nanyang Biologics (NYB), a leading drug discovery company dedicated to create transformative nutraceuticals derived from natural plants & herbs. This strategic partnership aims to revolutionize healthcare industry by delivering innovative, evidence-based products that enhance overall health and wellbeing, guided by rigorous scientific research and data-driven methodologies.
Fischer MV is known for its affordable, and accessible medical diagnostic and imaging technologies, by leveraging cutting-edge innovations and AI-powered software solutions in healthcare. As the first company to indigenously manufacture high-quality Magnetic Resonance Imaging (MRI) systems in India and owning a diverse portfolio of breakthrough diagnostic solutions, Fischer MV is moving into preventative healthcare space with NYB.
NYB aims to address the need for streamlined compound discovery, improved drug development efficiency, and targeted solutions for chronic diseases such as cancer and metabolic disorders, and to foster collaboration across sectors to drive innovation and accelerate the translation of research into impactful clinical applications, reducing time and resource burdens, and ultimately improving global healthcare outcomes.
Fischer Medical Ventures is engaged in the trading of certain grades of Laboratory Chemicals.
